A Structural Clue to Attacking Malaria's 'Achilles Heel'
TSRI and PATH collaboration provides blueprint for design of a next-generation vaccine
Washington DC, and La Jolla California, November 15, 2017—Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite through investigation of antibodies generated from the RTS,S malaria vaccine—work that could boost the development of a more potent vaccine against the global killer.
In a study published this week in the journal Proceedings of the National Academy of Sciences, the researchers provide an atomic-level view of how human antibodies bind to an important malarial surface protein, the circumsporozoite protein [CSP], to protect against the malaria parasite. These new structures could potentially help scientists enhance the efficacy and duration of RTS,S, the world's most advanced malaria vaccine to date, which has shown partial protection against the disease in a large-scale Phase 3 clinical trial.
The RTS,S vaccine was the outcome of a long-standing collaboration between PATH and GSK that began in 2001 and involved research institutions in Africa and around the world. RTS,S is the first and, to date, the only vaccine to show a protective effect against malaria among young children in Phase 3 clinical trials.
Efforts continue to enhance the vaccine's efficacy and duration of protection against malaria, a major public health problem that infects millions of people each year. An estimated 429,000 people died from the mosquito-borne illness in 2015 and 212 million people were infected.
Characterizing a key site of vulnerability on the malaria parasite
In this study, the investigators structurally characterized antibodies to CSP produced in response to a delayed fractional dose trial (MAL071) of the RTS,S vaccine. Ian Wilson, DSc, Hansen Professor of Structural Biology at TSRI, led the study. David Oyen, PhD, a research associate in Wilson's lab, is the first author.
"In order to design a next-generation vaccine, you need to know first the atomic details of highly protective antibody interaction," said Oyen. "Specifically, you need to know what part of the elicited antibodies recognizes what part of the malaria antigen."
"What Oyen and Wilson have done, together with the other collaborators, is to give us a very detailed picture of how those antibodies do the business of rejecting the (malaria) parasite, and that's very important," said Rick King, PhD, MVI's director of research and development and a co-author on the study. "This information will be very useful as we work to modify the existing vaccine so that it can be more protective."
In their study, Wilson and colleagues used X-ray crystallography and other sophisticated imaging technologies to analyze how two functional antibodies from RTS,S-vaccinated individuals latched onto the CSP protein target.
TSRI Professor Andrew Ward, PhD, a co-author whose lab provided electron microscopy expertise, said the researchers created structural images of the antibody binding to determine the precise area the immune system goes after.
"We were looking at what piece of the [CSP] protein the antibody is targeting," Ward said. "If we can focus the immune response on the real 'Achilles heel', the sites of vulnerability on the CSP protein, we would hope to get a more effective vaccine response."
The researchers drilled down to how the antibodies recognized the immunodominant NANP repeats within CSP, considered the area most important for eliciting a strong immune response and the basis for the RTS,S vaccine.
The research team pinpointed the number of NANP repeats that interacted with the two antibody fragments and established how the antibodies bind to the NANP repeat region.
"We found that these antibodies bind certain elements of the repeat peptides in a similar way," said Wilson, noting this information could be useful in engineering a next-generation vaccine. "The goal is to direct the immune system towards a particular region of the malaria pathogen surface protein to produce the type of antibodies that you know are or have a good possibility of being protective."
With this new structural map, the scientists have a better understanding of where the vaccine needs to be stabilized to better mimic CSP and "teach" the immune system to target malaria.
In addition to Wilson, Oyen, Ward, and King, other co-authors on the study, "Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein," were Jonathan L. Torres of TSRI; Ulrike Wille-Reece and Christian Ockenhouse of PATH's Malaria Vaccine Initiative; Daniel Emerling of Wayne Volkmuth of Atreca Inc.; Jacob Glanville of Stanford University; Yevel Flores-Garcia and Fidel Zavala of the Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health.
The study was supported by PATH's Malaria Vaccine Initiative under a collaborative agreement with TSRI.
For more information contact:
- Scripps Office of Communications | 858-784-2666 | firstname.lastname@example.org
- PATH Malaria Vaccine Initiative | Mary Hodges | email@example.com
About PATH's Malaria Vaccine Initiative
PATH's Malaria Vaccine Initiative (MVI) accelerates malaria vaccine development and catalyzes timely access in endemic countries, toward a world free from malaria. Standing at the intersection of malaria and immunization, MVI is part of PATH's Center for Malaria Control and Elimination and PATH's Center for Vaccine Innovation and Access. Learn more at www.malariavaccine.org.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.